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Precision medicine with modern immunotherapeutics
often requires pre-therapeutic access to novel and some-
times complex diagnostic tests. Test development and
access to tests including reimbursement often lacks
behind medicine development and availability of medi-
cines, potentially creating a gap for physicians to admin-
ister and patients to receive an optimised treatment
regime. Pharmaceutical companies are challenged by the
fact of having to co-develop a diagnostic method, a pro-
cess which many of them are not accustomed to. In addi-
tion, many healthcare systems have no way of allowing in
parallel evaluation of diagnostic test and medicine with a
view to reimbursement.
This presentation illustrates approaches using the devel-
opmental history of the MAGE-A3 cancer immunothera-
peutic to both address the developmental hurdle through
innovative models and partnerships, as well as the market
access hurdle through appropriate market understanding
and evidence generation.
Insights and solutions of pre-clinical, clinical and mar-
ket research/insight will be presented.
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